In this review we outline a rationale for identifying neuroprotectants aimed at inducing endogenous Klotho activity and expression, which is epigenetic action, by definition. Such an approach should promote remyelination and/or stimulate myelin repair by acting on mitochondrial function, thereby heralding a life-saving path forward for patients suffering from neuroinflammatory diseases. Disorders of myelin in the nervous system damage the transmission of signals, resulting in loss of vision, motion, sensation, and other functions depending on the affected nerves, currently with no effective treatment. Klotho genes and their single-pass transmembrane Klotho proteins are powerful governors of the threads of life and death, true to the origin of their name, Fates, in Greek mythology. Among its many important functions, Klotho is an obligatory co-receptor that binds, activates, and/or potentiates critical fibroblast growth factor activity. Since the discovery of Klotho a little over two decades ago, it has become ever more apparent that when Klotho pathways go awry, oxidative stress and mitochondrial dysfunction take over, and age-related chronic disorders are likely to follow. The physiological consequences can be wide ranging, potentially wreaking havoc on the brain, eye, kidney, muscle, and more. Central nervous system disorders, neurodegenerative in nature, and especially those affecting the myelin sheath, represent worthy targets for advancing therapies that act upon Klotho pathways. Current drugs for these diseases, even therapeutics that are disease modifying rather than treating only the symptoms, leave much room for improvement. It is thus no wonder that this topic has caught the attention of biomedical researchers around the world.
Background
The term ''epigenetics'' refers to changes resulting from modification of gene expression instead of alterations in the genetic code. 1 We postulate that drugs aimed at inducing endogenous Klotho activity and expression -that is, therapeutics acting through epigenetic mechanisms-should promote remyelination and/or stimulate myelin repair by acting on mitochondrial function. As such, this approach may herald a life-saving path forward for patients suffering from neuroinflammatory diseases.
Klotho-a gene set of three members: a-Klotho, b-Klotho, and g-Klotho 2-4 -is aptly named in the biological context of aging. 5, 6 According to Greek mythology, Klotho (or Clotho; Greek: Kkxh ), the youngest of the Fates (Clotho, Lachesis: L veri2 and Atropos:
sqopo2), is one of the three daughter deities (the spinner) of Zeus and Nyx (N n, the goddess of night) or Themis (Y li2, the goddess of law and order) who together spin out the thread of life, allot destiny, and choose the time of passing for both mortals and immortals. 7 Thus, nothing could be more appropriate than Klotho serving as a longevity gene. Indeed, once Klotho fails to adequately express its proteins and variants, 6, [8] [9] [10] it is implicated in pathways that drive agerelated chronic disorders such as kidney disease, tissue dysfunction, diabetic retinopathies, neurodegeneration, and impairments in mitochondrial function and muscle regeneration. 4, 8, [11] [12] [13] [14] [15] [16] a-Klotho is often referred to as an ''anti-aging protein.'' 3, 6, 17, 18 When overexpressed in mice, Klotho extends life (20-30%), reduces oxidative stress (OS), and demonstrates other prosurvival properties. [19] [20] [21] [22] [23] [24] [25] The potential of extending these results to humans has captured pharmaceutical interest in developing Klotho-based therapeutics to hinder the degenerative illnesses of aging. 5, 6, 8, [26] [27] [28] Noticeably, a growing body of evidence asserts the therapeutic potential of Klotho in treating neurodegenerative diseases. As population aging is a global phenomenon, 29 age-related neurodegenerative disorders are projected to surpass cancer as the foremost cause of death after cardiovascular disease in the developed world within 20 years. 30 The late-onset sporadic form (LOAD) of Alzheimer's disease (AD) [31] [32] [33] accounts for >90% of disease cases. 31, [34] [35] [36] Along with advanced aging, 23, [37] [38] [39] [40] [41] [42] [43] inheritance of the apolipoprotein E4 allele (also called APOE4 or APOEe4) remains the most significant known genetic risk factor for LOAD. The risk is higher and the age at onset of dementia is younger for individuals carrying multiple copies of APOE4, whereas other APOE alleles are considered protective. 31, 32, 44 In a study of a gene variant of Klotho with respect to AD in at-risk but presymptomatic individuals, heterozygosity was found to reduce amyloid aggregation in an APOE4-associated manner. 45 Of interest, in a research analysis that measured Klotho concentrations in the cerebrospinal fluid of AD subjects and in older versus younger adults, Klotho levels were found to be lower in women compared with men. 46, 47 Perhaps the latter observation may help to explain why women are more likely than men to have AD, although the reported difference may be the result of biological or social artifacts. 48 In addition to AD, the most common neurodegenerative disease, Parkinson's disease (PD), the second most common neurodegenerative disease, 49 has also been tied to Klotho pathways. [50] [51] [52] Beyond AD and PD, age-related declines in Klotho 8, 13, 17, 24, 53 are associated with a range of other deteriorating central nervous system (CNS) processes. 17, 24 For example, mounting evidence implicates dysregulation of Klotho in shared mechanistic pathological relationships linking iron and myelin in various common and rare brain diseases, [54] [55] [56] including abnormalities in myelination and the maturation of oligodendrocytes that are central to the pathogenicity of diseases such as multiple sclerosis (MS) 26, 56, 57 and amyotrophic lateral sclerosis (ALS). 56, 58 
OS Demyelination and Mitochondrial Dysfunction
Mitochondrial dysfunction is a well-documented enabling factor in the pathophysiology of neurological conditions and disorders ( Fig. 1 ). 41, [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] Although a principal role of mitochondria is to supply the bioenergy needed for cellular processes and maintenance, 69-71 mitochondria also help regulate neurite branching and regeneration as well as synaptic strength, stability, and signaling in the CNS. 72 In addition, myelin repair is intimately dependent on healthy mitochondrial function within the CNS in oligodendrocytes and neuronal cell bodies. 63, 64, [73] [74] [75] [76] [77] Dysfunctional mitochondria become sources of reactive oxygen species (ROS) that contribute to OS with deleterious effects on the cell's wellbeing. 61, 70, 71, 74, [77] [78] [79] [80] Manifestations of OS are hallmark symptoms in neurological disease, including cognitive deficits. 52, 54, 65, 76, 79, [81] [82] [83] [84] [85] [86] [87] [88] In concert with the above, a correlation was found between OS in the CNS and demyelination, which results in the loss of integrity and proper maintenance of oligodendrocytes and their myelin sheaths, the latter being crucial for cognitive performance and higher brain function. 57, [89] [90] [91] Thus, inclusion of strategies for enhancing mitochondrial biogenesis, function, and protection 68, 80, [92] [93] [94] [95] [96] that may also rely on pathways epigenetically induced by diet [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] and/or exercise 99,100,106-109 can be timely in the therapeutic protocols for treating myelination disorders. 68, [73] [74] [75] [76] 98, 104, [110] [111] [112] [113] [114] [115] Dysregulated Myelination in Peripheral and CNS Diseases Microglia are a distinct population of immune cells in the CNS. [116] [117] [118] They execute fundamental tasks in brain development, physiology, and homeostasis and in influencing the pathological progression of brain diseases. [117] [118] [119] [120] [121] [122] There is evidence to suggest that microglia actively remove damaged myelin 114, 123 to recruit myelinating cells, oligodendrocytes in the CNS, and Schwann cells in the peripheral nervous system (PNS) to repair the injured myelin sheath. 114, 117, 118, [123] [124] [125] Dysregulated myelination is a characteristic feature of numerous heritable neurological diseases, such as the PNS hereditary disorder, Charcot-Marie-Tooth disease, 126, 127 X-linked adrenoleukodystrophy and metachromatic leukodystrophy, 128 hereditary diffuse leukoencephalopathy with spheroids, Nasu-Hakola disease, 114 and Huntington's disease, 129, 130 among others. 55, 131, 132 A dysfunctional myelination apparatus is also evident in acquired demyelinating diseases such as diabetic peripheral neuropathy, drug-related peripheral neuropathies, leprosy, and peripheral neuropathies of inflammatory etiology. 132 Most interestingly, converging evidence drawn from ''Big Data'' analytics in parallel with epigenetic, neuroimaging, and experimental model investigations seems to connect an adult-onset form of attention-deficit/ hyperactivity disorder pathogenesis and persistence with dysregulated myelination. 133, 134 Many risk genes for CNS disorders such as AD, PD, schizophrenia, autism, and MS have been unveiled by genome-wide association studies to be expressed by microglia. 117 Dysfunction of microglia is common in neurological diseases 114 and recent studies have found that sex differences in microglial gene expression and functions seen in young adult mice tend to be increasingly pronounced in the aging brain. 135 Klotho as an Obligatory Co-receptor High concentrations of phosphate in the body are found in bone, teeth, and dental enamel as calcium phosphate crystals. 136, 137 Klotho regulates phosphorus and calcium homeostasis 5, 6, 18, 23, 138 and functions as an obligatory co-receptor that binds and activates its related endocrine fibroblast growth factor (FGF) receptors (FGFRs) to potentiate its biological activities. 5, 6, 23, 102, [139] [140] [141] [142] [143] [144] [145] [146] FGFs are exemplary pleiotropic hormones that play numerous roles in cellular and metabolic homeostasis. 5, 6, 137, 141, [144] [145] [146] [147] [148] In particular, FGF23 is a bone-derived hormone that in conjunction with Klotho acts on the kidney to increase phosphate excretion and suppress biosynthesis of vitamin D. 5, 6, 14, 23, 102, 136, 138, 145, 148, 149 Vitamin D regulates epigenetic mechanisms that maintain the transcription of its target genes in regulatory networks, including the expression of Klotho and nuclear factor-erythroid-2related factor 2 (Nrf2) to carry out many of its homoeostatic functions. 17, 97, [150] [151] [152] [153] Vitamin D is a modulator of the immune system, 154, 155 hence its mention here, and accumulating evidence suggests vitamin D deficiency is a risk factor for dysregulated Klotho-associated neurodegenerative diseases, the most noteworthy being MS. 9, 27, 52, 97, 102, 150, 152, 153, [156] [157] [158] Multiple Sclerosis MS is an insidious progressive neurodegenerative disease characterized by demyelinated lesions throughout the brain, spinal cord, and optic nerve resulting from immune-mediated attacks against myelin. [159] [160] [161] [162] [163] [164] [165] It is the apotheosis of myelination disorders that affects *2.5 million people around the world [166] [167] [168] and currently there are no definitive cures. The standard of chronic care, after using steroids for acute episodes, centers on the use of disease modifying therapies (DMTs) that modulate an overactive immune response, such as antibodies against interferon, interleukin, or related T cell targets. 9, [169] [170] [171] [172] Unfortunately, although there is a growing armamentarium of DMTs for neurodegenerative diseases, they have to date had only a modest impact on disease progression 173, 174 and thus the demand for myelin repair-promoting therapies for MS remains a significant unmet medical need. 159, [175] [176] [177] [178] The discovery of new drugs is a daunting, lengthy, and costly endeavor. Drug repurposing-based on mechanism of action and/or biological activity, not uncommonly the result of serendipity-is a promising and cost-saving approach for the treatment of rare genetic diseases and diseases with limited therapeutic options. 90, 104, 179, 180 This approach has yielded derivatives of the simple organic chemical, fumarate, including Vumerity (diroximel fumarate), which is reported to be better tolerated than Tecfidera, with fewer gastrointestinal side effects and more favorable pharmacokinetic properties. Vumerity is a delayed release formulation of an inactive diester prodrug of mono-methyl fumarate (Fig. 2) . Both Vumerity and Tecfidera are converted into the same pharmacologically active drug, monomethyl fumarate in vivo. 94, 163 The medical potential of dimethyl fumarate was identified over 60 years ago and marketed for the treatment of psoriasis. 181, 182 MS therapeutics approved by the U.S. Food and Drug Administration (FDA) are given in Table 1 .
Klotho Structure, Distribution, and Function in MS
Klotho is a single-pass transmembrane protein expressed in the brain (hippocampus and choroid plexus), kidney, eye (retina, optic nerve, lens) and parathyroid gland, and less so in other tissues. 3, 18, 27, 102, 183, 184 A soluble form of Klotho (sKlotho), primarily secreted from the kidney, circulates in blood, urine, and cerebrospinal fluid, exerting different biological effects in multiple tissues as a humoral factor. 5, 6, 8, 52, [185] [186] [187] [188] [189] In the eye, Klotho protects against OS 53, 55, 58, 153, 190, 191 and is essential to the proper maintenance and function of the ocular system, 12, 26, [192] [193] [194] [195] being expressed throughout the retina, with the highest levels in retinal ganglion cells. 196 The retinal pigment epithelium (RPE) is a highly specialized CNS tissue whose function is critical in preserving retinal homeostasis 53, 78 and an age-dependent decline of Klotho expression is said to contribute to RPE degeneration and retinal pathology. 53 Apoptotic cells in models of retinal degeneration were found to exhibit high levels of Klotho, 8 which is consistent with Klotho overexpression in its role as a protective protein that inhibits apoptosis. 22, 197, 198 A recent study has shown that higher levels of circulating Klotho protein is protective in patients with diabetic retinopathy. 199 Although the retina itself is a nonmyelinated tissue, 200 optic neuritis, a disease affecting the myelinated part of retinal ganglion cell axons, is a serious and often difficult to assess manifestation of MS, 201 particularly in the pediatric population. 202 More than 70% of MS patients suffer vision loss as a secondary effect of optic neuritis disease progression. 160, 203, 204 In recent studies, Klotho was shown to accelerate remyelination in a cuprizone-mediated demyelination mouse model. 9, 28 This important finding is refocusing attention on Klotho's role in neurodegeneration and research efforts are increasingly directed toward the develop-ment of MS treatments that promote remyelination and/or stimulate myelin repair. 9, 27, 28, 112, 166, 169, [205] [206] [207] [208] [209] [210] [211] However, because Klotho does not cross the bloodbrain barrier, 10,212 a small molecule approach aimed at inducing endogenous Klotho activity and expression in the CNS is surfacing as a promising therapeutic strategy. 27, 81, 90, 143, 213, 214 Epigenetics 10, 90, 100, 169, [215] [216] [217] [218] [219] and gene therapy-based methods are part of the emerging landscape under investigation. 19, 215, 220, 221 Amyotrophic Lateral Sclerosis The global prevalence of ALS is estimated to be roughly two to four cases per 100,000 population 222,223 compared with *30 cases per 100,000 population for MS. 168 ALS (also referred to as progressive muscular atrophy or Lou Gehrig's disease) is a devastating neurodegenerative disease. It damages motor neurons in the brain and spinal cord leading to progressive muscle atrophy and paralysis that is fatal, usually within 3-5 years of diagnosis. 58, [224] [225] [226] [227] Unfortunately, patients with ALS, at present, have limited therapeutic options (Table 2) . 96, 173, 228 Moreover, given the rapid and terminal progression of the disease postdiagnosis, there is a pressing need to develop new therapies and/or based on mechanism of action repurposing drugs already approved for other diseases. 176, 180 Recruiting ALS subjects into traditional clinical trials is challenging because of the low number of cases in the population. Trial-design protocols 229 that rely on restrictive inclusion criteria, frequent study visits, use of a placebo control arm that denies patients early access to the therapy, and the comparatively long time it takes to document results relative to the rapid progression of the disease are additional impediments. 230 Riluzole and edaravone, the principal therapeutics used in the treatment of ALS (Fig. 3) , have a modest impact on disease progression, extending survival by *3 months. 68, 96, 223, 231 The combination of dextromethorphan and quinidine sulfate has shown positive results against pseudobulbar affect (emotional lability) and is FDA-approved for ALS and MS, 232 although it is reported to be prescribed more to patients suffering from dementia or PD. 233 Clearly, much more effective therapies are needed and a vigorous research effort has been underway for the past several years to screen for and develop new pharmaceuticals for treating neurodegenerative diseases including ALS. 234, 235 Cromolyn sodium ( Fig. 3) , an FDA-approved compound used to treat asthma and other conditions has recently emerged as a promising new therapeutic for ALS. In the SOD1 G93A mouse model of ALS, treatment with cromolyn sodium delayed disease onset and showed neuroprotection by decreasing the inflammatory re-sponse. 236 However, a focus on myelination may lead to more lasting and effective therapeutic outcomes. Klotho overexpression in the SOD1 G93A mouse model was shown to suppress the production of proinflammatory cytokines, reduce the expression of neuroinflammatory markers, and prevent neuronal loss with a more profound effect in the spinal cord than in the motor cortex, thereby delaying the onset and progression of the disease. 58 These results along with the positive effect Klotho has on the promyelinating properties of oligodendrocytes offer compelling evidence in support of developing Klotho-based therapeutic strategies for treating ALS. 58 
Concluding Remarks
As outlined in the introduction, drugs aimed at inducing endogenous Klotho activity and expression-epigenetic action per se-should promote remyelination and/or stimulate myelin repair by acting on mitochondrial function. In the ensuing two decades since the serendipitous discovery of Klotho as an aging-suppressor gene, research has helped unmask many of its functional pathways in neurodegenerative disorders and/or dysregulated myelination (Fig. 4) . Deficient levels of Klotho protein lead to excessive OS induction mainly from ROS produced in mitochondrial dysfunction. Myelin repair is intimately dependent on the energy made available by healthy mitochondria within the CNS in oligodendrocytes (Schwann cells in the PNS) and neuronal cell bodies. Thus, drugs aimed at inducing endogenous Klotho production may herald a life-saving path forward for patients suffering from neuroinflammatory diseases. In parallel, much as the old psoriasis drug, dimethyl fumarate, was repurposed to treat MS, more drug repurposing may find worthwhile paths here too. Will AD, PD, MS, or ALS yield to these approaches when coupled with drugs that attack such a powerful pathway as Klotho? As we kick off what we hope will be ''the roaring 2020s'' when it comes to the advancement of major new life-saving therapeutics, time and effort toward this goal will hopefully give us the answers. is dedicated to Dr. Brenda Milner on the occasion of her 102 nd birthday.
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